Previous close | 18.08 |
Open | 18.17 |
Bid | 17.97 x N/A |
Ask | 18.06 x N/A |
Day's range | 18.17 - 18.17 |
52-week range | 15.37 - 20.99 |
Volume | |
Avg. volume | 186 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Shares of GSK (GSK) are falling after a Centers for Disease Control and Prevention (CDC) committee shifted its recommendation on Respiratory Syncytial Virus (RSV) vaccination dosages. Yahoo Finance reporter Anjalee Khemlani joins Morning Brief to break down this latest development for GSK and what the CDC announcement could mean for the company moving forward. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Nicholas Jacobino.
The simplest way to invest in stocks is to buy exchange traded funds. But one can do better than that by picking better...
GSK shares are today’s major focus after the drugs giant’s defence against Zantac claims suffered a setback in a Delaware court. The FTSE 100 index is trading higher after Friday’s late rally by Wall Street markets was further boosted by this week’s prospect of an ECB interest rate cut. Other companies in the spotlight today include FTSE 250-listed Hollywood Bowl, having posted an 11% rise in half-year profits.